<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460979</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-GYN 8</org_study_id>
    <nct_id>NCT01460979</nct_id>
  </id_info>
  <brief_title>Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma</brief_title>
  <official_title>Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the activity, tolerability and safety of
      Temsirolimus in women with ovarian cancer who progressed during the previous platinum
      chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>after 4 months for ovarian cancer and 6 months for endometrial carcinoma after study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate and duration of stable diseases according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG)-criteria for ovarian cancer</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival according to RECIST 1.1 and cancer antigen 125 (CA 125) (for ovarian cancer) (biological progression-free survival (PFSbio))</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>weekly until progression; thereafter every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and toxicity, i.e. type, frequency, severity and duration of adverse reactions</measure>
    <time_frame>weekly until progression; thereafter every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) questionaires &quot;QLQ C30&quot;, &quot;QLQ OV28&quot; and &quot;QLQ-EN24&quot;</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate and duration of stable diseases according to RECIST-criteria for endometrial cancer</measure>
    <time_frame>every 8 weeks until progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Genital Diseases, Female</condition>
  <condition>Ovarian Diseases</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Endometrial Neoplasms</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25mg weekly intravenous until progression</description>
    <arm_group_label>Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          -  Before performance of study specific actions or assessment the patient has to be
             informed, has signed the written consent and is willing to follow the requirements
             concerning treatment and follow-up.Comment: Procedures which are according to common
             clinical routine and having been performed before having given written informed
             consent may be used for the purpose of screening procedures or initial medical
             assessment as long as these procedures follow the protocol.

          -  Required: negative pregnancy test in fertile women

        Stratum A - Ovarian Cancer:

          -  Histologically confirmed Ovarian Cancer

          -  Platin-refractory relapsed disease: progression within a platin-based chemotherapy or
             within 6 months after completion of a platin-based chemotherapy

          -  Prior treatment with a taxane-based scheme

          -  minimum of one measurable or non-measurable tumor lesion(according to RECIST 1.1
             criteria)

          -  Not more than 2 previous chemotherapies or cytostatic therapies (i.e. monoclonal
             antibodies, cytokines, signal transduction inhibitors)

        Stratum B - Endometrian Cancer:

          -  Histologically confirmed Endometrian Cancer

          -  Advanced (International Federation of Gynaecology and Obstetrics (FIGO) III or IV) or
             relapsed diseases not amenable to potentially curative treatment with local surgery
             and/or radiation therapy

          -  Prior endocrine therapy is allowed

          -  Prior adjuvant chemotherapy is allowed

          -  Minimum of one measurable or non-measurable tumor lesion(according to RECIST 1.1
             criteria)

        Exclusion Criteria:

          -  ECOG &gt; 2

          -  Prior therapy with mammalian target of rapamycin (mTOR) -Inhibitor

          -  Cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal transduction
             inhibitors), cytotoxical chemotherapy or endocrine therapy or radiation at the same
             time

          -  Current or recent treatment with another study drug and/or participation in another
             clinical study within 28 days prior to first dose of study treatment

          -  Chemotherapy or cytostatic therapy (i.e. monoclonal antibodies, cytokines, signal
             transduction inhibitors) or radiation within 28 days prior to start of study treatment

          -  Known or supposed hypersensitivity compared to study medication

          -  Acute or chronical infection

          -  Second malignancy which influences the prognosis of the patient

          -  Inadequate renal function (Creatinin &gt; 1.5 x Upper Limit of Normal (ULN))

          -  Inadequate liver function (aspartate transaminase (AST), alanine transaminase (ALT),
             gamma-Glutamyl transpeptidase (GGT) &gt; 2.5 x ULN or &gt; 5.0 x ULN in the presence of
             liver metastasis; Bilirubin &gt; 1.5 x ULN)

          -  Platelets &lt; 100.000 /μl; Absolute Neutrophil Count (ANC) &lt; 1.500 /μl

          -  Cachectic patients with weight &lt; 45kg

          -  Patients who need parenteral nutrition

          -  Patients with ileus within the last 28 days

          -  One of the following diseases within 12 months prior to first study treatment:
             myocardial infarction, severe/unstable angina, bypass surgery of the coronar- or
             peripheral vessels, symptomatic heart insufficiency, cerebrovascular insult, transient
             ischemic attack (TIA), pulmonary embolism, deep venous thrombosis, other
             thromboembolic events

          -  Current treatment with Cytochrome P450 3A4 (CYP3A4) -Inhibitors (i.e. protease
             inhibitors, antimycotics, calcium channel blocker, macrolide antibiotics, Cimetidine)
             or -inductors (i.e. Carbamazepin, Phenobarbital, Phenytoin, Rifampicin, amber)

          -  Uncontrolled hypertension (&gt; 150/100 mmHg despite optimal medicinal treatment)

          -  Current cardiac arrhythmias (Common Terminology Criteria for Adverse Events of
             National Cancer Institute (NCI CTCAE) grade ≥ 2), atrial fibrillation, prolongation of
             QTc &gt; 470 msec

          -  Left ventricular ejection fraction (LVEF) ≤ 50% defined by echocardiogram

          -  NCI CTCAE grade 3 hemorrhage within 4 weeks prior to beginning of treatment

          -  Symptoms which indicate brain metastases, spinal cord compression or give new
             indications for brain- or leptomeningeal metastases

          -  Human immunodeficiency virus (HIV) positive or manifested Acquired Immune Deficiency
             Syndrome (AIDS-disease)

          -  Patients with other severe diseases who represent an inadequate risk for study
             participation

        Applicable only for patients with no hysterectomy and/or bilateral adnexectomy prior to
        start of study.

          -  lactation

          -  potential fertile women without adequate contraception (potential fertile women must
             use one of the following adequate contraception: complete abstinence, intrauterine
             spiral or another method with a failure quote &lt; 1% per year)

          -  life expectancy &lt; 3 months

          -  neurological or psychiatric diseases or drugs or alcohol abuse which suppose no
             adequate comprehension and consequently no effective consent to study participation or
             no acceptable compliance during the study

          -  predictable problems with the compliance to appointments for examinations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Günter Emons, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>AGO Study Group (Study Group of the Arbeitsgemeinschaft Gynaekologische Onkologie)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen-Marburg, Standort Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Offenbach</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald der Ernst-Moritz-Arndt-Universität</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Göttingen, Georg-August-Universität</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum Solingen gGmbH</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42653</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GYNAEKOLOGICUM Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26731724</url>
    <description>Final publication</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <keyword>Temsirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

